These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial. Chen GL; Coates EE; Plummer SH; Carter CA; Berkowitz N; Conan-Cibotti M; Cox JH; Beck A; O'Callahan M; Andrews C; Gordon IJ; Larkin B; Lampley R; Kaltovich F; Gall J; Carlton K; Mendy J; Haney D; May J; Bray A; Bailer RT; Dowd KA; Brockett B; Gordon D; Koup RA; Schwartz R; Mascola JR; Graham BS; Pierson TC; Donastorg Y; Rosario N; Pape JW; Hoen B; Cabié A; Diaz C; Ledgerwood JE; JAMA; 2020 Apr; 323(14):1369-1377. PubMed ID: 32286643 [TBL] [Abstract][Full Text] [Related]
3. Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice. Arévalo MT; Huang Y; Jones CA; Ross TM PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007316. PubMed ID: 31026260 [TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial. Bennett SR; McCarty JM; Ramanathan R; Mendy J; Richardson JS; Smith J; Alexander J; Ledgerwood JE; de Lame PA; Royalty Tredo S; Warfield KL; Bedell L Lancet Infect Dis; 2022 Sep; 22(9):1343-1355. PubMed ID: 35709798 [TBL] [Abstract][Full Text] [Related]
5. A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults. Shaw CA; August A; Bart S; Booth PJ; Knightly C; Brasel T; Weaver SC; Zhou H; Panther L Vaccine; 2023 Jun; 41(26):3898-3906. PubMed ID: 37210308 [TBL] [Abstract][Full Text] [Related]
6. Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus. DeZure AD; Berkowitz NM; Graham BS; Ledgerwood JE J Infect Dis; 2016 Dec; 214(suppl 5):S497-S499. PubMed ID: 27920180 [TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults†. McMahon R; Fuchs U; Schneider M; Hadl S; Hochreiter R; Bitzer A; Kosulin K; Koren M; Mader R; Zoihsl O; Wressnigg N; Dubischar K; Buerger V; Eder-Lingelbach S; Jaramillo JC J Travel Med; 2024 Mar; 31(2):. PubMed ID: 38091981 [TBL] [Abstract][Full Text] [Related]
8. Immunological implications of diverse production approaches for Chikungunya virus-like particle vaccines. Thompson D; Metz SW; Abad C; Beaty S; Warfield K Vaccine; 2022 May; 40(22):3009-3017. PubMed ID: 35459557 [TBL] [Abstract][Full Text] [Related]
9. Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice. Zhao Z; Deng Y; Niu P; Song J; Wang W; Du Y; Huang B; Wang W; Zhang L; Zhao P; Tan W Front Immunol; 2021; 12():655743. PubMed ID: 33868299 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Ramsauer K; Schwameis M; Firbas C; Müllner M; Putnak RJ; Thomas SJ; Desprès P; Tauber E; Jilma B; Tangy F Lancet Infect Dis; 2015 May; 15(5):519-27. PubMed ID: 25739878 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Reisinger EC; Tschismarov R; Beubler E; Wiedermann U; Firbas C; Loebermann M; Pfeiffer A; Muellner M; Tauber E; Ramsauer K Lancet; 2019 Dec; 392(10165):2718-2727. PubMed ID: 30409443 [TBL] [Abstract][Full Text] [Related]
12. A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes. Goo L; Dowd KA; Lin TY; Mascola JR; Graham BS; Ledgerwood JE; Pierson TC J Infect Dis; 2016 Nov; 214(10):1487-1491. PubMed ID: 27655868 [TBL] [Abstract][Full Text] [Related]
17. Bacteriophage Qβ virus-like particles displaying Chikungunya virus B-cell epitopes elicit high-titer E2 protein antibodies but fail to neutralize a Thailand strain of Chikungunya virus. Basu R; Zhai L; Rosso B; Tumban E Vaccine; 2020 Mar; 38(11):2542-2550. PubMed ID: 32044164 [TBL] [Abstract][Full Text] [Related]
18. Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose. Abeyratne E; Tharmarajah K; Freitas JR; Mostafavi H; Mahalingam S; Zaid A; Zaman M; Taylor A Front Immunol; 2020; 11():304. PubMed ID: 32194557 [TBL] [Abstract][Full Text] [Related]
19. A chikungunya fever vaccine utilizing an insect-specific virus platform. Erasmus JH; Auguste AJ; Kaelber JT; Luo H; Rossi SL; Fenton K; Leal G; Kim DY; Chiu W; Wang T; Frolov I; Nasar F; Weaver SC Nat Med; 2017 Feb; 23(2):192-199. PubMed ID: 27991917 [TBL] [Abstract][Full Text] [Related]
20. The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials. Essink B; Chu L; Seger W; Barranco E; Le Cam N; Bennett H; Faughnan V; Pajon R; Paila YD; Bollman B; Wang S; Dooley J; Kalidindi S; Leav B Lancet Infect Dis; 2023 May; 23(5):621-633. PubMed ID: 36682364 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]